Corvus terminates ATM equity programs with Jefferies

Corvus Pharmaceuticals, Inc.

Terminated 2020 Sales Agreement (up to $50M) and 2021 Sales Agreement (up to $40M) with Jefferies LLC effective March 28, 2023.
Both at-the-market offering programs are no longer available for use.
No reason for termination provided in the filing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Corvus Pharmaceuticals, Inc. terminated Sales Agreements with Jefferies LLC valued at At-the-Market Offering Program with aggregate offering price up to $50.0 million (2020) and up to $4 (effective 2023-03-28).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Value: At-the-Market Offering Program with aggregate offering price up to $50.0 million (2020) and up to $4
Effective: 2023-03-28

Exact text from the filing

On March 28, 2023, the Company terminated the Sales Agreements effective immediately. As a result, the At-the-Market Offering Programs under each of the 2020 Sales Agreement and 2021 Sales Agreement are no longer available for use.

View on SEC.gov

Browse all material agreements →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-082785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.